Corporate Overview

Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

28.5 Million

Adult Americans may suffer from Chronic Idiopathic Constipation (CIC)

11.5 Million

Adult Americans may have Irritable Bowl Syndrome with Constipation (IBS-C)

~4.5 Million

Unique Patients since the launch of LINZESS

Featured Reports

Featured Events

Recent News